Clinical review of a long-acting, injectable formulation of risperidone-Reference-Cited by-同舟云学术

Clinical review of a long-acting, injectable formulation of risperidone

Published:2004-12 Issue:12 Volume:26 Page:1994-2002
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Knox Erin Danielle,Stimmel Glen L.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Overview of partial compliance;Marder;J Clin Psychiatry,2003

2. Depot neuroleptic therapy: An underutilized option;Glazer;J Clin Psychiatry,1992

3. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia;Bhanji;Eur Neuropsychopharmacol,2004

4. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics;Ereshefsky;J Clin Psychiatry,2003

5. Risperidone;Livingston;Lancet,1994

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications;European Journal of Medicinal Chemistry;2024-11

2. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches;Expert Opinion on Pharmacotherapy;2023-06-27

3. Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group;Pharmaceutical Research;2023-02-22

4. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia;Cochrane Database of Systematic Reviews;2022-11-24

5. Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review;Advances in Therapy;2022-09-01